Cleo Diagnostics Ltd
Research Cleo Diagnostics Ltd (COV.AX) on Bullrun: market cap AUD 44.14M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCOV.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryMedical Devices
- CurrencyAUD
- Market capAUD 44.14M
- Financial periodFY2026
- Net income-AUD 5.94M
- Free cash flow-AUD 4.95M
Valuation Snapshot
latest market cap is AUD 44.14M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | n/a | -AUD 5.94M | -AUD 4.95M | n/a | -0.04 | AUD 6.22M | n/a | AUD 5.01M |
| FY2025 | n/a | -AUD 4.00M | -AUD 2.91M | n/a | -0.03 | AUD 6.46M | n/a | AUD 5.83M |
| FY2024 | n/a | -AUD 3.76M | -AUD 2.03M | n/a | -0.03 | AUD 9.37M | n/a | AUD 10.61M |
| FY2023 | n/a | -AUD 1.73M | -AUD 1.02M | n/a | -0.07 | AUD 239.77K | AUD 1.60M | -AUD 943.42K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-17 | AUD 44.14M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Cleo Diagnostics Ltd
Cleo Diagnostics Ltd, a biotechnology company, engages in the development and patent of a blood test for the detection of ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property, testing the IP, and securing patents.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cleo Diagnostics Ltd's market cap?
Cleo Diagnostics Ltd's market capitalization is AUD 44.14M.
What does Cleo Diagnostics Ltd do?
Cleo Diagnostics Ltd, a biotechnology company, engages in the development and patent of a blood test for the detection of ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property, testing the IP, and securing patents. Cleo Diagnostics Ltd was incorporated in 2021 and is based in Melbourne, Australia.